A randomized, placebo-controlled, double-blind study on the effects of (−)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects

• Published in: International journal of cardiology Vol. 223; pp. 500 - 506
• Main Authors: Gutiérrez-Salmeán, Gabriela, Meaney, Eduardo, Lanaspa, Miguel A., Cicerchi, Christina, Johnson, Richard J., Dugar, Sundeep, Taub, Pam, Ramírez-Sánchez, Israel, Villarreal, Francisco, Schreiner, George, Ceballos, Guillermo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.11.2016
• Subjects: Adolescent; Adult; Cardiometabolic risk; Cardiovascular; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - etiology; Catechin - therapeutic use; Cells, Cultured; Cholesterol, HDL - blood; Double-Blind Method; Epicatechin; Female; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Hypertriglyceridemia - etiology; Male; Metabolic syndrome; Metabolic Syndrome - blood; Metabolic Syndrome - drug therapy; Metabolic Syndrome - etiology; Middle Aged; Nutraceutics; Plasma triglycerides; Risk Factors; Triglyceride-HDL ratio; Triglycerides - blood; Young Adult; Cardiometabolic risk; Metabolic syndrome; Triglyceride-HDL ratio; Nutraceutics; Epicatechin; Plasma triglycerides

Cardiometabolic disruptions such as insulin resistance, obesity, high blood pressure, hyperglycemia, and dyslipidemias, are known to increase the risk for cardiovascular and metabolic diseases such as type 2 diabetes mellitus and atherosclerosis. Several screening tools for assessing cardiometabolic...